AbCellera Biologics ABCL

$ 2.82 4.06%

Quarterly report 2024-Q3
added 11-04-2024

AbCellera Biologics Balance Sheet 2011-2024 | ABCL

Annual Balance Sheet AbCellera Biologics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-55.9 M	-304 M	-461 M	-592 M	-3.72 M	-7 M	-	-	-	-	-	-	-
Long Term Debt	71.2 M	76.7 M	36.4 M	2.2 M	1.36 M	911 K	-	-	-	-	-	-	-
Long Term Debt Current	6.16 M	5.58 M	3.65 M	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	217 M	189 M	172 M	71.5 M	5.34 M	3.45 M	-	-	-	-	-	-	-
Total Current Liabilities	119 M	118 M	121 M	-	-	-	-	-	-	-	-	-	-
Total Liabilities	336 M	308 M	293 M	175 M	13.2 M	9.88 M	-	-	-	-	-	-	-
Deferred Revenue	19 M	21.6 M	7.54 M	7.53 M	3.24 M	2.33 M	-	-	-	-	-	-	-
Retained Earnings	280 M	426 M	268 M	114 M	-4.72 M	-2.5 M	-	-	-	-	-	-	-
Total Assets	1.49 B	1.54 B	1.32 B	1.01 B	23.5 M	21.5 M	-	-	-	-	-	-	-
Cash and Cash Equivalents	133 M	387 M	501 M	594 M	-	-	-	-	-	-	-	-	-
Book Value	1.15 B	1.23 B	1.03 B	831 M	10.3 M	11.6 M	-	-	-	-	-	-	-
Total Shareholders Equity	1.15 B	1.23 B	1.03 B	831 M	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet AbCellera Biologics

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	66.3 M	66.5 M	68.1 M	71.2 M	75.2 M	78.1 M	77.3 M	76.7 M	71.6 M	32.8 M	36.4 M	36.4 M	27.3 M	31 M	17 M	3.72 M	3.72 M	3.72 M	3.72 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	235 M	231 M	228 M	217 M	219 M	223 M	200 M	189 M	196 M	160 M	171 M	172 M	170 M	114 M	83 M	71.5 M	71.5 M	71.5 M	71.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	315 M	302 M	333 M	336 M	329 M	342 M	289 M	308 M	302 M	381 M	385 M	293 M	219 M	184 M	171 M	175 M	175 M	175 M	175 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	5.58 M	6.4 M	10.6 M	19 M	17.5 M	8.54 M	11.8 M	21.6 M	6.82 M	4.62 M	9.19 M	7.54 M	6.17 M	10.6 M	11.3 M	6.59 M	6.59 M	6.59 M	6.59 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	151 M	202 M	239 M	280 M	327 M	356 M	386 M	426 M	456 M	429 M	436 M	268 M	208 M	229 M	231 M	114 M	114 M	114 M	114 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	1.39 B	1.41 B	1.46 B	1.49 B	1.51 B	1.54 B	1.5 B	1.54 B	1.55 B	1.59 B	1.59 B	1.32 B	1.17 B	1.15 B	1.13 B	1.01 B	1.01 B	1.01 B	1.01 B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	127 M	148 M	124 M	133 M	197 M	205 M	218 M	387 M	397 M	816 M	571 M	476 M	518 M	793 M	686 M	594 M	594 M	594 M	594 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	1.08 B	1.11 B	1.13 B	1.15 B	1.18 B	1.19 B	1.21 B	1.23 B	1.25 B	1.21 B	1.21 B	1.03 B	953 M	968 M	957 M	831 M	831 M	831 M	831 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	1.08 B	1.11 B	1.13 B	1.15 B	1.18 B	1.19 B	1.21 B	1.23 B	1.25 B	1.21 B	1.21 B	1.03 B	953 M	968 M	957 M	831 M	831 M	831 M	831 M	10.3 M	-	-	-	11.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency